ArticleWomen's health reports (New Rochelle, N.Y.)2025
Comparative Effectiveness of Tibolone and Combined Hormone Therapy in Relieving Menopausal Insomnia.
Article in Women's health reports (New Rochelle, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study explores the effectiveness of tibolone and combined hormone therapy (HT) in alleviating sleep disorders in women aged 40-65 who are in menopausal transition and postmenopause. Methods: The ambidirectional cohort study (retrospective 2011-2015; prospective 2016-2021), conducted at Shanghai Sixth People's Hospital's specialized menopause clinic. Participants were given tibolone or combined HT based on their STRAW + 10 stratification and preference for continued menstruation. Demographic information, baseline, and reevaluated performance of the Pittsburgh Sleep Quality Index (PSQI) were collected for analysis of their differentiations and impact factors. Sleep quality was reassessed 12 months after treatment initiation Results: The cohort study involved 285 participants-184 in the tibolone cohort and 101 in the combination HT cohort. After 12 months, PSQI scores improved by -3.76 ± 4.12 with tibolone and -3.66 ± 4.23 with combined HT. The adjusted between group difference was -0.359 (95% confidence interval = 0.577; Conclusions: The study suggests that tibolone and combined HT improved sleep to a similar extent after adjustment. Further comprehensive research is necessary to corroborate these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.